BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 22433846)

  • 1. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa.
    Fox MP; Cutsem GV; Giddy J; Maskew M; Keiser O; Prozesky H; Wood R; Hernán MA; Sterne JA; Egger M; Boulle A;
    J Acquir Immune Defic Syndr; 2012 Aug; 60(4):428-37. PubMed ID: 22433846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa.
    Rohr JK; Ive P; Horsburgh CR; Berhanu R; Shearer K; Maskew M; Long L; Sanne I; Bassett J; Ebrahim O; Fox MP
    PLoS One; 2016; 11(8):e0161469. PubMed ID: 27548695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa.
    Onoya D; Nattey C; Budgell E; van den Berg L; Maskew M; Evans D; Hirasen K; Long LC; Fox MP
    AIDS Patient Care STDS; 2017 May; 31(5):205-212. PubMed ID: 28445088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda.
    Ssempijja V; Nakigozi G; Chang L; Gray R; Wawer M; Ndyanabo A; Kasule J; Serwadda D; Castelnuovo B; Hoog AV; Reynolds SJ
    BMC Infect Dis; 2017 Aug; 17(1):582. PubMed ID: 28830382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa.
    Evans D; Hirasen K; Berhanu R; Malete G; Ive P; Spencer D; Badal-Faesen S; Sanne IM; Fox MP
    AIDS Res Ther; 2018 Apr; 15(1):10. PubMed ID: 29636106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Mortality With Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South Africa.
    Bell Gorrod H; Court R; Schomaker M; Maartens G; Murphy RA
    J Acquir Immune Defic Syndr; 2020 May; 84(1):107-113. PubMed ID: 32032304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
    Hermans LE; Moorhouse M; Carmona S; Grobbee DE; Hofstra LM; Richman DD; Tempelman HA; Venter WDF; Wensing AMJ
    Lancet Infect Dis; 2018 Feb; 18(2):188-197. PubMed ID: 29158101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring.
    ; Keiser O; Tweya H; Boulle A; Braitstein P; Schecter M; Brinkhof MW; Dabis F; Tuboi S; Sprinz E; Pujades-Rodriguez M; Calmy A; Kumarasamy N; Nash D; Jahn A; MacPhail P; Lüthy R; Wood R; Egger M
    AIDS; 2009 Sep; 23(14):1867-74. PubMed ID: 19531928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa.
    Petersen ML; Tran L; Geng EH; Reynolds SJ; Kambugu A; Wood R; Bangsberg DR; Yiannoutsos CT; Deeks SG; Martin JN
    AIDS; 2014 Sep; 28(14):2097-107. PubMed ID: 24977440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term virological outcome in children receiving first-line antiretroviral therapy.
    Chandrasekaran P; Shet A; Srinivasan R; Sanjeeva GN; Subramanyan S; Sunderesan S; Ramesh K; Gopalan B; Suresh E; Poornagangadevi N; Hanna LE; Chandrasekar C; Wanke C; Swaminathan S
    AIDS Res Ther; 2018 Nov; 15(1):23. PubMed ID: 30477526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa.
    Fox MP; Berhanu R; Steegen K; Firnhaber C; Ive P; Spencer D; Mashamaite S; Sheik S; Jonker I; Howell P; Long L; Evans D
    Trop Med Int Health; 2016 Sep; 21(9):1131-7. PubMed ID: 27383454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line antiretroviral therapy: long-term outcomes in South Africa.
    Murphy RA; Sunpath H; Castilla C; Ebrahim S; Court R; Nguyen H; Kuritzkes D; Marconi VC; Nachega JB
    J Acquir Immune Defic Syndr; 2012 Oct; 61(2):158-163. PubMed ID: 22692090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
    Chang LW; Harris J; Humphreys E
    Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa.
    De Luca A; Marazzi MC; Mancinelli S; Ceffa S; Altan AM; Buonomo E; Prosperi MC; Pedruzzi B; Noorjehan AM; Scarcella P; Liotta G; Palombi L
    J Acquir Immune Defic Syndr; 2012 Mar; 59(3):236-44. PubMed ID: 22327246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa.
    Shearer K; Evans D; Moyo F; Rohr JK; Berhanu R; Van Den Berg L; Long L; Sanne I; Fox MP
    Trop Med Int Health; 2017 Feb; 22(2):221-231. PubMed ID: 27797443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes.
    Moorhouse M; Maartens G; Venter WDF; Moosa MY; Steegen K; Jamaloodien K; Fox MP; Conradie F
    J Acquir Immune Defic Syndr; 2019 Jan; 80(1):73-78. PubMed ID: 30334876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration.
    Davies MA; Moultrie H; Eley B; Rabie H; Van Cutsem G; Giddy J; Wood R; Technau K; Keiser O; Egger M; Boulle A;
    J Acquir Immune Defic Syndr; 2011 Mar; 56(3):270-8. PubMed ID: 21107266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
    ; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS
    Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes after virologic failure of first-line ART in South Africa.
    Murphy RA; Sunpath H; Lu Z; Chelin N; Losina E; Gordon M; Ross D; Ewusi AD; Matthews LT; Kuritzkes DR; Marconi VC;
    AIDS; 2010 Apr; 24(7):1007-12. PubMed ID: 20397305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.